Nasdaq: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College ... Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College ... Nasdaq: Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension Seeking Alpha: Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension Mineralys Therapeutics announced the results of the Phase 3 Launch-HTN trial, the largest hypertension study involving an aldosterone synthase inhibitor, which included over 1,000 participants with ...
– Topline data from the trial are expected in the first half of 2024 – – A second, pivotal trial of lorundrostat in uncontrolled and resistant hypertension expected to commence enrollment in the ...
